{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:13:26Z","timestamp":1790097206309,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing-Tianjin-Hebei Basic Research Project of Tianjin Science and Technology Bureau","award":["22JCZXJC00040"],"award-info":[{"award-number":["22JCZXJC00040"]}]},{"name":"Public Health Science and Technology Major Project of the Tianjin Science and Technology Bureau","award":["21ZXGWSY00020"],"award-info":[{"award-number":["21ZXGWSY00020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Triple-negative breast cancer (TNBC) is characterized by complex genomic background and treatment resistance. We first defined \u201cTitin (TTN) inactivation\u201d, a state of TTN expression deficiency or mutation, affecting tumor progression. However, how TTN inactivation regulates immune escape and affects therapeutic resistance remains unclear. Using whole-exome sequencing, single-cell transcriptome sequencing, and spatial transcriptome sequencing, we screened the clinical features of TNBC patients with TTN inactivation who accepted neoadjuvant therapy. Meanwhile, we used CRISPR-Cas9 technology to construct various mutant TNBC cell lines. Lentiviral vector carrying TTN and delta-like ligand 4 (DLL4) was validated in vivo to verify potential mechanism. Myeloid-derived suppressor cells (MDSCs) metabolic function was measured using glycolysis-related molecular experiments. Immunotherapeutic agents against TNBC with TTN inactivation were explored in the orthotopic MCT4\n                    <jats:sup>fl\/fl<\/jats:sup>\n                    genetically modified mouse model. DLL4-regulated ecological niche was established in TNBC with TTN inactivation. Mechanistically, TTN deficiency and mutation led to DLL4 secretion in TNBC. DLL4 enhanced MCT4-mediated glycolysis via MDSCs-derived NOTCH2 signaling pathway, driving the malignant function and lactate acid excretion of MDSCs. DLL4-derived MDSCs promoted stemness-mediated drug resistance by inducing histone lactate modification in TNBC, suppressing the anti-tumor activities of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. Blocking the DLL4-MCT4 axis stimulated anti-tumor immunity and synergized with anti-PD-1, improving response rates for first-line neoadjuvant therapy in TNBC. Our study revealed intrinsic mechanism by which TTN regulates the tumor immune microenvironment and provided a potential target for immunotherapy in TNBC with TTN inactivation.\n                  <\/jats:p>","DOI":"10.1186\/s43556-025-00372-6","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:47:30Z","timestamp":1764647250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Delta-like ligand 4 mediated myeloid-derived suppressor cell metabolic reprogramming promotes neoadjuvant therapy resistance in titin-inactivated triple-negative breast cancer"],"prefix":"10.1186","volume":"6","author":[{"given":"Yanfang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parhat","family":"Kaysar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhansheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"372_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2025.03.004","author":"YS Pao","year":"2025","unstructured":"Pao YS, Liao KJ, Shiau YC, Chao MH, Li MC, Lin LM, et al. KIF2C promotes paclitaxel resistance by depolymerizing polyglutamylated microtubules. Dev Cell. 2025. https:\/\/doi.org\/10.1016\/j.devcel.2025.03.004.","journal-title":"Dev Cell"},{"issue":"2","key":"372_CR2","doi-asserted-by":"publisher","first-page":"e70047","DOI":"10.1002\/ddr.70047","volume":"86","author":"K Chen","year":"2025","unstructured":"Chen K, Zhao Y, Jin T, Xu T, Zhu C, Shen H, et al. Serum amyloid A1 mediates paclitaxel resistance via MD2-dependent pathways in triple-negative breast cancer. Drug Dev Res. 2025;86(2):e70047. https:\/\/doi.org\/10.1002\/ddr.70047.","journal-title":"Drug Dev Res"},{"key":"372_CR3","doi-asserted-by":"publisher","first-page":"117351","DOI":"10.1016\/j.biopha.2024.117351","volume":"179","author":"H Qayoom","year":"2024","unstructured":"Qayoom H, Mir MA. Mutant P53 modulation by cryptolepine through cell cycle arrest and apoptosis in triple negative breast cancer. Biomed Pharmacother. 2024;179:117351. https:\/\/doi.org\/10.1016\/j.biopha.2024.117351.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"372_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13073-024-01286-8","volume":"16","author":"G Yin","year":"2024","unstructured":"Yin G, Liu L, Yu T, Yu L, Feng M, Zhou C, et al. Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy. Genome Med. 2024;16(1):11. https:\/\/doi.org\/10.1186\/s13073-024-01286-8.","journal-title":"Genome Med"},{"key":"372_CR5","doi-asserted-by":"publisher","first-page":"117955491986848","DOI":"10.1177\/1179554919868482","volume":"13","author":"CH Saravia","year":"2019","unstructured":"Saravia CH, Flores C, Schwarz LJ, Bravo L, Zavaleta J, Araujo J, et al. Patterns of mutation enrichment in metastatic triple-negative breast cancer. Clin Med Insights Oncol. 2019;13:1179554919868482. https:\/\/doi.org\/10.1177\/1179554919868482.","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"372_CR6","doi-asserted-by":"publisher","first-page":"20524","DOI":"10.1038\/s41598-022-25059-8","volume":"12","author":"Y Lv","year":"2022","unstructured":"Lv Y, Bai Z, Wang X, Liu J, Li Y, Zhang X, et al. Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model. Sci Rep. 2022;12(1):20524. https:\/\/doi.org\/10.1038\/s41598-022-25059-8.","journal-title":"Sci Rep"},{"key":"372_CR7","doi-asserted-by":"publisher","first-page":"1176647","DOI":"10.3389\/fimmu.2023.1176647","volume":"14","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Xu J, Xu Y, Sun S, Chen J. Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer. Front Immunol. 2023;14:1176647. https:\/\/doi.org\/10.3389\/fimmu.2023.1176647.","journal-title":"Front Immunol"},{"key":"372_CR8","doi-asserted-by":"publisher","unstructured":"Sun E, Liu X, Lu C, Liu K. Long non\u2011coding RNA TTN\u2011AS1 regulates the proliferation, invasion and migration of triple\u2011negative breast cancer by targeting miR\u2011211\u20115p. Mol Med Rep. 2021;23(1). https:\/\/doi.org\/10.3892\/mmr.2020.11683.","DOI":"10.3892\/mmr.2020.11683"},{"issue":"7","key":"372_CR9","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1016\/j.apsb.2024.03.008","volume":"14","author":"M Dong","year":"2024","unstructured":"Dong M, Zhang Y, Chen M, Tan Y, Min J, He X, et al. ASF1A-dependent P300-mediated histone H3 lysine 18 lactylation promotes atherosclerosis by regulating EndMT. Acta Pharm Sin B. 2024;14(7):3027\u201348. https:\/\/doi.org\/10.1016\/j.apsb.2024.03.008.","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"372_CR10","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/1078-0432.Ccr-10-2560","volume":"17","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-2560.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"372_CR11","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.4161\/cc.10.10.15703","volume":"10","author":"Z Jiang","year":"2011","unstructured":"Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011;10(10):1563\u201370. https:\/\/doi.org\/10.4161\/cc.10.10.15703.","journal-title":"Cell Cycle"},{"issue":"1","key":"372_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41467-017-00921-w","volume":"8","author":"N Riaz","year":"2017","unstructured":"Riaz N, Blecua P, Lim RS, Shen R, Higginson DS, Weinhold N, et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nat Commun. 2017;8(1):857. https:\/\/doi.org\/10.1038\/s41467-017-00921-w.","journal-title":"Nat Commun"},{"key":"372_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41525-019-0107-6","volume":"5","author":"JH Oh","year":"2020","unstructured":"Oh JH, Jang SJ, Kim J, Sohn I, Lee JY, Cho EJ, et al. Spontaneous mutations in the single TTN gene represent high tumor mutation burden. NPJ Genom Med. 2020;5:33. https:\/\/doi.org\/10.1038\/s41525-019-0107-6.","journal-title":"NPJ Genom Med"},{"issue":"1","key":"372_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13395-018-0156-z","volume":"8","author":"M Savarese","year":"2018","unstructured":"Savarese M, Jonson PH, Huovinen S, Paulin L, Auvinen P, Udd B, et al. The complexity of titin splicing pattern in human adult skeletal muscles. Skeletal Muscle. 2018;8(1):11. https:\/\/doi.org\/10.1186\/s13395-018-0156-z.","journal-title":"Skeletal Muscle"},{"key":"372_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cellsig.2018.08.011","volume":"51","author":"X Liu","year":"2018","unstructured":"Liu X, Li C, Zhang R, Xiao W, Niu X, Ye X, et al. The EZH2-H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo\/YAP pathway upstream effector, in breast cancer epithelial cells. Cell Signal. 2018;51:243\u201356. https:\/\/doi.org\/10.1016\/j.cellsig.2018.08.011.","journal-title":"Cell Signal"},{"issue":"1","key":"372_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1074\/jbc.M114.603589","volume":"290","author":"Z Tan","year":"2015","unstructured":"Tan Z, Xie N, Banerjee S, Cui H, Fu M, Thannickal VJ, et al. The monocarboxylate transporter 4 is required for glycolytic reprogramming and inflammatory response in macrophages. J Biol Chem. 2015;290(1):46\u201355. https:\/\/doi.org\/10.1074\/jbc.M114.603589.","journal-title":"J Biol Chem"},{"issue":"7","key":"372_CR17","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1002\/cam4.1587","volume":"7","author":"SYC Choi","year":"2018","unstructured":"Choi SYC, Ettinger SL, Lin D, Xue H, Ci X, Nabavi N, et al. Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. Cancer Med. 2018;7(7):3385\u201392. https:\/\/doi.org\/10.1002\/cam4.1587.","journal-title":"Cancer Med"},{"key":"372_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2017.07.022","volume":"406","author":"K Zhao","year":"2017","unstructured":"Zhao K, Wang Q, Wang Y, Huang K, Yang C, Li Y, et al. EGFR\/c-myc axis regulates TGF\u03b2\/Hippo\/Notch pathway via epigenetic silencing miR-524 in gliomas. Cancer Lett. 2017;406:12\u201321. https:\/\/doi.org\/10.1016\/j.canlet.2017.07.022.","journal-title":"Cancer Lett"},{"key":"372_CR19","doi-asserted-by":"publisher","first-page":"102254","DOI":"10.1016\/j.ceb.2023.102254","volume":"85","author":"H Cuervo","year":"2023","unstructured":"Cuervo H, M\u00fchleder S, Garc\u00eda-G\u00f3nzalez I, Benedito R. Notch-mediated cellular interactions between vascular cells. Curr Opin Cell Biol. 2023;85:102254. https:\/\/doi.org\/10.1016\/j.ceb.2023.102254.","journal-title":"Curr Opin Cell Biol"},{"issue":"4","key":"372_CR20","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.bbrc.2018.05.091","volume":"501","author":"Z Li","year":"2018","unstructured":"Li Z, Wu Q, Sun S, Wu J, Li J, Zhang Y, et al. Monocarboxylate transporters in breast cancer and adipose tissue are novel biomarkers and potential therapeutic targets. Biochem Biophys Res Commun. 2018;501(4):962\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2018.05.091.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"372_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.humimm.2022.01.014","volume":"83","author":"CM Worsley","year":"2022","unstructured":"Worsley CM, Veale RB, Mayne ES. The acidic tumour microenvironment: manipulating the immune response to elicit escape. Hum Immunol. 2022;83(5):399\u2013408. https:\/\/doi.org\/10.1016\/j.humimm.2022.01.014.","journal-title":"Hum Immunol"},{"issue":"3","key":"372_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10637-018-0665-y","volume":"37","author":"A Jimeno","year":"2019","unstructured":"Jimeno A, Moore KN, Gordon M, Chugh R, Diamond JR, Aljumaily R, et al. A first-in-human phase 1a study of the bispecific anti-DLL4\/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest New Drugs. 2019;37(3):461\u201372. https:\/\/doi.org\/10.1007\/s10637-018-0665-y.","journal-title":"Invest New Drugs"},{"issue":"3","key":"372_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.43","volume":"1","author":"Z Gu","year":"2022","unstructured":"Gu Z. Complex heatmap visualization. Imeta. 2022;1(3):e43. https:\/\/doi.org\/10.1002\/imt2.43.","journal-title":"Imeta"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00372-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-025-00372-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00372-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:47:30Z","timestamp":1764647250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-025-00372-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["372"],"URL":"https:\/\/doi.org\/10.1186\/s43556-025-00372-6","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental studies and animal care were performed in accordance with the guidelines and endorsement of the Tianjin Medical University Cancer Hospital Animal Center. The approval number of animal experiment is NSFC-AE-2025240.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}